Several sector-linked finance items highlighted activity across biotech-adjacent health tech and broader biopharma capital markets. Health tech funding rounds were reported as a cluster of July announcements, while an Omics/diagnostics stock basket tracked by GenomeWeb rose on average month over month. In the GenomeWeb Top 40, shares gained about 6% in July as life science tools and diagnostics outperformed broader markets. CareDx posted the largest gain after MolDx issued a finalized local coverage determination tied to molecular testing reimbursement and after the company reported a revenue jump, while Seer’s shares surged on competing takeover bids. The combined picture points to ongoing capital and liquidity dynamics in diagnostics, tools, and select oncology-adjacent plays—where reimbursement signals and corporate transactions can move valuations quickly.